Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

被引：20

作者：

Sidana, Surbhi ^{[1
]}

Ahmed, Nausheen ^{[2
]}

Akhtar, Othman S. ^{[3
]}

Heim, Michael ^{[4
]}

Brazauskas, Ruta ^{[4
,5
]}

Hansen, Doris K. ^{[6
]}

Ferreri, Christopher ^{[7
]}

Freeman, Ciara Louise L. ^{[8
]}

Afrough, Aimaz ^{[9
]}

Anderson, Larry D., Jr. ^{[10
]}

Dhakal, Binod ^{[11
]}

Dhanda, Devender ^{[12
]}

Gowda, Lohith ^{[13
,14
]}

Hashmi, Hamza ^{[15
]}

Harrison, Melanie ^{[16
]}

Kitali, Amani

Mirza, Sayeef ^{[17
]}

Patel, Jinalben ^{[4
]}

Patwardhan, Pallavi ^{[16
]}

Usmani, Saad Z. ^{[18
]}

Patel, Krina K. ^{[19
]}

Ganguly, Siddhartha ^{[20
,21
]}

Pasquini, Marcelo ^{[4
]}

机构：

[1] Stanford Univ, Stanford, CA USA

[2] Univ Kansas, Canc Ctr, Westwood, KS USA

[3] Moffit Canc Ctr, Tampa, FL USA

[4] Med Coll Wisconsin, CIBMTR R Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI USA

[5] Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[9] UT SouthWestern Med Ctr, Dallas, TX USA

[10] UT SouthWestern Med Ctr, Myeloma Waldenstroms & Amyloidosis Program, Hematol Malignancies & Cellular Therapy Program, Simmons Comprehens Canc Ctr, Dallas, TX USA

[11] Med Coll Wisconsin, BMT & Cellular Therapy, Div Hematol & Oncol, Dept Med, Milwaukee, WI USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Yale Canc Ctr, New Haven, CT USA

[14] Yale Sch Med, New Haven, CT USA

[15] Med Univ South Carolina, Charleston, SC USA

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Yale Sch Med, New Haven, CT USA

[18] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplant Serv, Dept Med, New York, NY USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Houston Methodist Hosp, Houston, TX USA

[21] Neal Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181762

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[41] Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.
Afrough, Aimaz
Hashmi, Hamza
Hansen, Doris K.
Sidana, Surbhi
Ahn, Chul
Dima, Danai
Freeman, Ciara L.
Puglianini, Omar Alexis Castaneda
Kocoglu, Mehmet H.
Atrash, Shebli
Voorhees, Peter M.
Shune, Leyla
Simmons, Gary
Sborov, Douglas W.
Ferreri, Christopher J.
Wagner, Charlotte Burton
Patel, Krina K.
Khouri, Jack
Anderson, Larry D., Jr.
Lin, Yi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[42] Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Munshi, Nikhil C.
Anderson, Larry D., Jr.
Shah, Nina
Madduri, Deepu
Berdeja, Jesus
Lonial, Sagar
Raje, Noopur
Lin, Yi
Siegel, David
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Cavo, Michele
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Rambaldi, Alessandro
Reece, Donna
Petrocca, Fabio
Massaro, Monica
Connarn, Jamie N.
Kaiser, Shari
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08): : 705 - 716
[43] French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry
Cayla, Sarah
Ferment, Benoit
Bigot, Noemie
Caillot, Denis
Lafon, Ingrid
Karlin, Lionel
Lazareth, Anne
Touzeau, Cyrille
Leleu, Xavier
Moya, Niels
Harel, Stephanie
Perrot, Aurore
Bories, Pierre
Vincent, Laure
Lamure, Sylvain
Mohty, Mohamad
Malard, Florent
Manier, Salomon
Yakoub-Agha, Ibrahim
Stoppa, Anne-Marie
Brisou, Gabriel
Decaux, Olivier
Houot, Roch
Le Gouill, Steven
Lambert, Jerome
Facon, Thierry
Loiseau, Herve Avet
Moreau, Philippe
Arnulf, Bertrand
BLOOD, 2023, 142
[44] Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: real-world experience
Hansen, Doris
Sidana, Surbhi
Peres, Lauren
Leitzinger, Christelle Colin
Shune, Leyla
Shrewsbury, Alexandria
Gonzalez, Rebecca
Sborov, Douglas
Wagner, Charlotte
Hashmi, Hamza
Kocoglu, Mehmet
Atrash, Shebli
Simmons, Gary
Kalariya, Nilesh
Ferreri, Christopher
Afrough, Aimaz
Kansagra, Ankit
Voorhees, Peter
Baz, Rachid
Khouri, Jack
Alsina, Melissa
McGuirk, Joseph
Locke, Frederick
Patel, Krina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S2 - S3
[45] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
Weisel, K.
Manier, S.
Kansagra, A.
Anderson, Jr L. D.
Berdeja, J.
Jagannath, S.
Lin, Y.
Lonial, S.
Shah, N.
Raje, N.
Siegel, D.
Oriol, A.
Truppel-Hartmann, A.
Rowe, E.
Patel, P.
Agarwal, A.
Campbell, T. B.
Rodriguez-Otero, P.
Munshi, N.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180
[46] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
Einsele, Hermann
Berdeja, Jesus
Raje, Noopur
Siegel, David
Lin, Yi
Anderson, Larry, Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy
Jagannath, Sundar
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
[47] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
Einsele, H.
Berdeja, J.
Raje, N. S.
Siegel, D. S.
Lin, Y.
Anderson, L. D., Jr.
Rodriguez-Otero, P.
Manier, S.
Cavo, M.
Truppel-Hartmann, A.
Rowe, E.
Sanford, J.
Wang, J.
Campbell, T. B.
Jagannath, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
[48] A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma
Hansen, Doris
Peres, Lauren
Dima, Danai
Richards, Alicia
Shune, Leyla
Afrough, Aimaz
Midha, Shonali
Dhakal, Binod
Kocoglu, Mehmet H.
Ferreri, Christopher
Davis, James
Herr, Megan
Forsberg, Peter
Janakiram, Murali
Reshef, Ran
Sborov, Douglas W.
Khouri, Jack
Richard, Shambavi
Martin, Thomas
Lin, Yi
Patel, Krina
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S5 - S5
[49] KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath
Yi Lin
Hartmut Goldschmidt
Donna Reece
Ajay Nooka
Alicia Senin
Paula Rodriguez-Otero
Ray Powles
Kosei Matsue
Nina Shah
Larry D. Anderson
Matthew Streetly
Kimberly Wilson
Hoa Van Le
Arlene S. Swern
Amit Agarwal
David S. Siegel
Blood Cancer Journal, 11
[50] A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma
Shah, Nina
Ayers, Dieter
Davies, Faith E.
Cope, Shannon
Mojebi, Ali
Parikh, Kejal
Dhanda, Devender
Hari, Parameswaran
Patel, Payal
Huang, Liping
Hege, Kristen
Dhanasiri, Sujith
BLOOD, 2020, 136

← 1 2 3 4 5 →